HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Ömer Isik Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kirali, K. Articles by Yakut, C. Search for Related Content PubMed PubMed Citation Articles by Kirali, K. Articles by Yakut, C. Related Collections Valve disease

Ann Thorac Surg 2001;71:811-815
© 2001 The Society of Thoracic Surgeons

---

Original article: cardiovascular

Fifteen-year clinical experience with the Biocor porcine bioprostheses in the mitral position

^a Department of Cardiovascular Surgery, Kouyolu Heart and Research Hospital, Istanbul, Turkey

Accepted for publication October 14, 2000.

Address reprint requests to Dr Kirali, Kouyolu Heart and Research Hospital, 81020, Kadiköy, Istanbul, Turkey
e-mail: kosuyolu{at}superonline.com

Background. Bioprosthetic valve use represents a crucial improvement in surgical treatment of mitral valve disease. The aim of this study is to determine the long-term durability of the Biocor porcine bioprosthetic mitral valve.

Methods. Between 1985 and 1989, a total of 158 Biocor porcine bioprosthetic valves were placed in the mitral position, and long-term results of these patients were investigated retrospectively in 1999.

Results. Thirty-day mortality was 4.4% (7 patients). Total follow-up was 1,499 patient-years. Actuarial survival was 83.66% ± 3% at 5 years, 77.78% ± 3.36% at 13 years (1.8% patient-year). Multivariate analysis demonstrated younger age, duration of implantation, congestive heart failure, and functional class to be significant predictors of late mortality. Actuarial freedom from valve-related mortality was 98.58% ± 1% at 15 years (0.13% patient-year). Actuarial freedom from structural valve deterioration was 95.49% ± 1.8% at 5 years, 70.2% ± 4.12% at 10 years, and 64.82% ± 5.34% at 13 years (2.6% patient-year). Actuarial freedom from structural valve deterioration-related reoperation was 98.43% ± 1.1% at 5 years, 89.15% ± 2.85% at 10 years, and 76.82% ± 7.91% at 14 years. Multivariate analysis showed younger age and duration of implantation to be significant predictors of structural valve deterioration and its related reoperation.

Conclusions. By studying a 15-year time period, it is seen that this new generation porcine bioprosthetic valve should be considered an alternative for mechanical valves in selected patients.

This article has been cited by other articles:

				S. Kabbani, H. Jamil, F. Nabhani, A. Hamoud, K. Katan, N. Sabbagh, A. Koudsi, L. Kabbani, and G. Hamed Analysis of 92 mitral pulmonary autograft replacement (Ross II) operations. J. Thorac. Cardiovasc. Surg., October 1, 2007; 134(4): 902 - 908.e7. [Abstract] [Full Text] [PDF]

				L. S. De Santo, G. Romano, A. D. Corte, F. Tizzano, A. Petraio, C. Amarelli, M. De Feo, G. Dialetto, M. Scardone, and M. Cotrufo Mitral mechanical replacement in young rheumatic women: Analysis of long-term survival, valve-related complications, and pregnancy outcomes over a 3707-patient-year follow-up J. Thorac. Cardiovasc. Surg., July 1, 2005; 130(1): 13 - 19. [Abstract] [Full Text] [PDF]

				G. Rizzoli, T. Bottio, V. Vida, G. Nesseris, L. Caprili, G. Thiene, and G. Gerosa Intermediate results of isolated mitral valve replacement with a Biocor porcine valve J. Thorac. Cardiovasc. Surg., February 1, 2005; 129(2): 322 - 329. [Abstract] [Full Text] [PDF]